HBCUs are behind the effort to study the genetic variants that affect Black people

In a groundbreaking project, scientists are assembling genetic data from 500,000 people of African descent to establish the most extensive genomic database for this demographic. The endeavor, initiated by Meharry Medical College in collaboration with pharmaceutical leaders like Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche, aims to develop a novel "reference genome." This comprehensive genetic blueprint could illuminate specific genetic variants that significantly affect the health of Black individuals, potentially paving the way for the development of new medications and diagnostic procedures.

The initiative addresses a stark gap in genetic research, where less than 2% of current genetic studies involve people of African ancestry. The project stands apart from ongoing research efforts, with a distinct focus on enlisting historically Black colleges and universities (HBCUs) in the U.S. and institutions like the University of Zambia in Africa for volunteer recruitment. The extensive process, expected to span five years, ensures anonymity and involves detailed genetic sequencing, with the resultant data managed by the Diaspora Human Genomics Institute.

This venture isn't solely about genetic research; it's also about fostering collaboration and education. The data repository will be exclusive to HBCUs and affiliated African institutions, encouraging global scientific cooperation. Furthermore, the project encompasses a broader educational aspect, with a grant program supporting genomics research at Meharry and STEM initiatives for younger students in diverse communities. The corporate stakeholders have committed substantial funding, highlighting the project's scale and potential impact on healthcare and education.